摘要
目的 检测肝细胞癌 (HCC)患者介入前后血清血管内皮细胞生长因子 (VEGF)水平与HCC转移复发的关系。方法 采用酶联免疫吸附 (ELISA)法检测 40例健康人和 64例行介入治疗的HCC患者血清中的VEGF水平 ,并与其临床转移复发情况进行对照分析。结果 64例HCC患者血清中VEGF含量 (2 0 4 .1 5± 1 34 .2 8)ng/L明显高于健康人群 (2 6 .1 2± 2 4 .58)ng/L(P<0 .0 1 ) ;介入治疗后HCC患者血清VEGF(2 65 .46± 2 57.36)ng/L高于治疗前 (2 0 4 .1 5± 1 34 .2 8)ng/L(P <0 .0 5) ;高转移复发倾向组HCC病人血清VEGF(345 .68± 348.36)ng/L明显高于低转移复发倾向组 (2 2 4 .1 8± 1 39.2 6)ng/L(P <0 .0 1 ) ;HCC血清中的VEGF水平与肿瘤有无包膜、门静脉癌栓、复发转移密切相关 (P <0 .0 5)。结论 HCC患者介入治疗后VEGF明显升高 。
Objective To study the relationship between serum vascular endothelial growth factor (VEGF) as a predictor for metastatic recurrence and transcatheter arterial chemoebolization (TACE) in hepatocellular carcinoma (HCC).Methods Enzyme linked immunosorbent assay (ELISA) was used to detect serum levels of VEGF collected from 40 healthy individuals,64 HCC patients of transcatheter arterial chemoebolization respectively.Results Serum levels of VEGF in 64 patients with HCC was significantly higher than in healthy individuals(P<0.01),Serum levels of VEGF in high tendency to metastatic recurrence group were significantly higher than those in low tendency to metastatic recurrence group (P<0.01). Serum level of VEGF signifcantly correlated ,nonencapsulated ,metastatic recurrencein,portal thrombosis of HCC patients with TACE(P<0.01).Conclusion Serum VEGF is a potential predictor for prognosis of metastatic recurrence in HCC.Metastatic recurrence can be elevated with TACE in HCC.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2002年第5期417-418,共2页
Chinese Journal of Experimental Surgery
关键词
原发性肝癌
介入治疗
内皮细胞生长因子
肿瘤转移
肿瘤复发
Hepatocellular carcinoma
Chemotherapy
Endothelial cell derived growth factors
Neoplasm metastatic,neoplasm recurrence
